中國生命集團(08296.HK)於中國設合營開展生物科技業務
格隆匯9月27日丨中國生命集團(08296.HK)公佈,於2019年8月2日,本公司全資附屬公司中科臻祺與江濤先生(獨立第三方)及艾時代(本公司關連人士)訂立合營協議,以於中國成立合營公司以開展生物科技業務。合營公司的註冊資本為人民幣2400萬元,及中科臻祺須於2020年12月31日之前支付注資人民幣720萬元,佔合營公司30%的股份權益。
合營公司將主要從事生物醫學技術的開發、轉讓、推廣及科技服務(不包括人體幹細胞、基因診斷及治療技術的開發及應用);研發、生產及銷售食品以及經許可化粧品;開發及生產醫學設備及裝置;租賃生物醫學實驗室、生產線及平台;以及提供業務管理及諮詢服務。
公司稱,由於細胞技術漸趨成熟,且該行業一直以來備受國家支持,本集團看好細胞產業的長期發展前景。而細胞培養基作為細胞產業的具有高技術的上游產品,國內目前主要依賴進口。因此,掌握該技術以實現進口替代至關重要。
憑藉合營協議訂約各方的專業知識及資源,預期合營公司將成為細胞產業上游具有競爭優勢的企業。此次擴張亦符合本集團發展規劃,並優化本集團業務架構、增強本集團競爭力及創造力。本集團將藉此進一步推動業績增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.